secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-04-05T23:59:59+00:00
Accession:  0001683168-22-002335
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte Biotech appoints Dr. Matthias Löhr to Board to fill vacancy from Yuen's death
--------------------------------------------------------------------------------

- Dr. Löhr appointed to Board on March 31, 2022; vacancy created by death of Thomas C.K. Yuen.
- Compensation: $12,500 cash per quarter, annual grant of 334 restricted shares and a 5-year option for 334 shares (fully vested).
- Dr. Löhr is Professor of Gastroenterology & Hepatology at Karolinska Institute; led prior Phase 1/2 and Phase 2 trials of the company's pancreatic cancer treatment.
- He will serve on the Compensation and Nominating Committees; independence under Nasdaq rules confirmed.
- No family relationships or related party transactions with the company disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822002335/0001683168-22-002335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822002335/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-002335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer